Acute kidney injury (AKI) represents the most frequent complication after cardiac surgery. Macrophage migration inhibitory factor (MIF) is a stress-regulating cytokine that was shown to protect the heart from myocardial ischemiareperfusion injury, but its role in the pathogenesis of AKI remains unknown. In an observational study, serum and urinary MIF was quantified in 60 patients scheduled for elective conventional cardiac surgery with the use of cardiopulmonary bypass. Cardiac surgery triggered an increase in MIF serum concentrations, and patients with high circulating MIF (>median) 12 hours after surgery had a significantly reduced risk of developing AKI (relative risk reduction, 72.7%; 95% confidence interval, 12 to 91.5%; P = 0.03). Experimental AKI was induced in wild-type and Mif −/− mice by 30 min of ischemia followed by 6 or 24 hours of reperfusion, or by rhabdomyolysis. Mif-deficient mice exhibited increased tubular cell injury, increased regulated cell death (necroptosis and ferroptosis), and enhanced oxidative stress. Therapeutic administration of recombinant MIF after ischemia-reperfusion in mice ameliorated AKI. In vitro treatment of tubular epithelial cells with recombinant MIF reduced cell death and oxidative stress as measured by glutathione and thiobarbituric acid reactive substances in the setting of hypoxia. Our data provide evidence of a renoprotective role of MIF in experimental ischemia-reperfusion injury by protecting renal tubular epithelial cells, consistent with our observation that high MIF in cardiac surgery patients is associated with a reduced incidence of AKI.
INTRODUCTION
Open-heart surgery is associated with considerable morbidity, with acute kidney injury (AKI) being one of the most frequently observed postoperative complications (1) . Postoperative AKI determines the outcome and lethality of patients, resulting in considerable costs for the health care system (2-4). Hemodynamic instability, an excessive inflammatory response, and perioperative release of reactive oxygen species (ROS) are involved in the pathogenesis of cardiac surgeryrelated AKI (1, 5, 6) . Prolonged anesthesia, perioperative drug treatment, operative trauma, and patient positioning in the setting of cardiac surgery can contribute to rhabdomyolysis (skeletal muscle break down) and further increase the risk of postoperative AKI (7) (8) (9) .
Macrophage migration inhibitory factor (MIF) is an inflammatory and stress-regulating cytokine with chemokine-like functions that is rapidly released in response to various stimuli from preformed, intracellular pools, in contrast to other innate mediators that require transcriptional activation and synthesis before release (10, 11) . MIF exerts its effects via binding and activating its receptors, CXCR2, CXCR4, and CD74, with subsequent recruitment and phosphorylation of its co-receptor CD44. CXCR2 and CXCR4 are chemokine receptors involved in inflammatory actions of MIF and in the pathogenesis of various diseases, including myocardial infarction, atherosclerosis, and sepsis (12, 13) . In contrast, CD74 was suggested to mediate protective effects of MIF, particularly in cardiac ischemia-reperfusion (I/R) injury (14) (15) (16) . Recently, a soluble form of the CD74 ectodomain, sCD74, was identified (17) . In observational studies of sepsis and liver transplantation, increased MIF in the serum was associated with severe AKI (18, 19) . Comparable to sepsis, cardiac surgery with use of cardiopulmonary bypass (CPB) is associated with systemic oxidative stress and hemodynamic changes, resulting in a transiently decreased perfusion of organs, including the kidney. We and others have demonstrated that MIF is elevated during the perioperative inflammatory response after cardiac surgery (20, 21) . Several studies have revealed cardioprotective effects of MIF in the setting of acute myocardial I/R injury (20, 22, 23) , but the functional role and clinical relevance of MIF in the development of postoperative AKI remain unknown.
Renal tubular epithelial cell injury and cell death contribute to the pathophysiology of AKI (24) . The role of apoptosis as the key mechanism of tubular injury and AKI has recently been challenged (25) (26) (27) . We and others have previously demonstrated alternative pathways of regulated cell death, in particular necroptosis and ferroptosis, as crucial pathophysiological pathways of AKI (25, 26) . Necroptosis is a form of regulated necrosis and is mediated by receptor-interacting protein kinase-3-dependent phosphorylation of mixed lineage kinase domain-like (MLKL) (24) . When MLKL is phosphorylated, it leads to permeabilization of cellular membranes and necrotic cellular demise (28) . Oxidative stress is considered a relevant stimulus for the development of cardiac surgery-associated AKI by driving cell death, in particular ferroptosis (5) . Ferroptosis is another form of regulated necrotic cell death. It is characterized by iron-dependent lipid peroxidation and is initiated by intracellular glutathione (GSH) depletion (24) . A currently favored hypothesis deems ferroptosis as a trigger of subsequent synchronized renal tubular necrosis (29) .
MIF was shown to have antioxidant properties (20) (21) (22) (23) (24) , potentially by its thiol-protein oxidoreductase (TPOR) activity. Here, we tested the hypothesis that MIF might be a protective factor limiting AKI through cytoprotective and antioxidative effects, using a comprehensive combined clinical and experimental approach including the stateof-the-art assessment of apoptosis, necroptosis, and ferroptosis.
RESULTS
Elevated MIF is associated with reduced incidence of AKI in cardiac surgery patients Baseline characteristics of the patients included in this prospective, observational study are provided in table S1 and fig. S1 . Concurrent with previous findings (30) , MIF concentration in serum peaked directly after cardiac surgery, followed by a gradual decline in the postoperative period until day 1 ( fig. S2A ). Compared to patients with low postoperative serum MIF (below the median value), patients with high serum MIF showed a reduced incidence of AKI 12 hours after surgery (relative risk reduction, 72.7%; 95% confidence interval, 12 to 91.5%; P = 0.030; Table 1 S2D ). Postoperative serum MIF inversely correlated with postoperative urinary NGAL (0 hours after surgery, P = 0.038; r = −0.321; r = 0.103; 24 hours after surgery, P = 0.009; r = −0.408; r = 0.167) (Fig. 1E) .
MIF is associated with the total antioxidant capacity after cardiac surgery
The total antioxidant capacity in the patients' serum was measured using the RedoxSYS Diagnostic System (Luoxis Diagnostics). After cardiac surgery, the total antioxidant capacity rapidly decreased and remained low during the postoperative time course (Fig. 1F) . Patients with high postoperative serum MIF (higher than the median value) immediately (0 hours) after surgery had a significantly elevated total antioxidant capacity when compared to low postoperative serum MIF (lower than the median value) at the corresponding time point (P = 0.04; Fig. 1G ). Although the antioxidant capacity in patients with low serum MIF started to decline early between pre-OP and 0 hours after surgery, the total antioxidant capacity remained stable in patients with high postoperative MIF (>median value) directly (0 hours) after surgery and showed a delayed decrease within the first 6 hours after surgery (P = 0.004). No significant differences in the antioxidant capacity were detected at the other perioperative time points. Patients who developed postoperative AKI had significantly reduced total antioxidant capacity before surgery (P = 0.04) and immediately (0 hours) after surgery (P = 0.03) when compared to patients without AKI (Fig. 1, H and I ).
Renal ischemia induces MIF release into the plasma
To investigate whether renal ischemia might be associated with MIF release into the bloodstream, we assessed kinetics of circulating MIF in patients with surgery-induced renal ischemia during kidney tumor enucleation. Patients with temporary renal ischemia by clamping of the kidney artery showed a significant increase in MIF during and after surgery (P = 0.01), whereas there was no significant increase in MIF in patients undergoing tumor enucleation without renal ischemia (P = 0.25; Fig. 2A ). The duration of renal ischemia correlated positively with postoperative circulating MIF shortly after surgery, in the recovery room, and on the first postoperative day (POD1) (recovery room, P = 0.045; r = 0.676; POD1, P = 0.0005; r = 0.738; r = 0.545; Fig. 2B ).
Mif deficiency aggravates tubular injury and regulates cell death after I/R injury and in rhabdomyolysis-induced AKI
To assess the functional role of MIF in AKI in vivo and to identify potential mechanisms, we compared the degree of acute tubular injury and regulated cell death in wild-type (WT) and Mif-deficient (Mif 
Mif deficiency increases immune cell infiltration
In line with the more severe tubular injury, Mif −/− kidneys showed significantly aggravated inflammatory cell infiltration of Erhr3 + macrophages, F4/80 + monocytes and dendritic cells, and Ly6G + granulocytes at 24 hours after I/R injury and after rhabdomyolysis (Fig. 5 , A and C). At 6 hours after I/R injury, the immune cell infiltration of Ly6G + granulocytes was significantly increased in Mif −/− mice (cortex, P = 0.001; outer medulla, P = 0.03), whereas the number of F4/80 + monocytes was only significantly increased in the cortex (P < 0.001) but not in the outer medulla (P = 0.13; Fig. 5B ). In accordance with the observation of increased immune cell infiltration, the relative mRNA expression of Cxcl-1, a chemotactic cytokine for granulocytes and monocytes, was significantly higher in Mif −/− mice compared to WT mice 6 hours after hypoxia (P = 0.04; Fig. 5D ).
MIF reduces oxidative stress and lipid peroxidation in vitro and in vivo
Oxidative stress was induced by incubation with hydrogen peroxide (H 2 O 2 ) or mice; hpf, high-power field. Scale bars, 100 m. Data are means ± SD; *P < 0.05, **P < 0.01 analyzed by Student's t test.
hypoxia in primary murine tubular epithelial cells (pmTECs), which were left untreated or were pretreated with recombinant MIF (rMIF). MIF treatment increased intracellular GSH as shown by a higher intracellular GSH/GSSG (reduced glutathione/glutathione disulfide) ratio (H 2 O 2 , P = 0.02; hypoxia, P = 0.04; Fig. 6A ). Similarly, thiobarbituric acid reactive substances (TBARS), which is a widely used marker of lipid peroxidation (32), was significantly reduced in pmTECs incubated with rMIF and exposed to hypoxia, compared to untreated cells (P = 0.005; Fig. 6B ). Consistent with these in vitro findings, we found significantly lower GSH and higher TBARS in tissue lysates of Mif −/− mice after I/R and rhabdomyolysis compared to WT mice (GSH: 6 hours I/R, P = 0.03; 24 hours I/R, P = 0.04; rhabdomyolysis, P = 0.005; TBARS: 6 hours I/R, P = 0.04; 24 hours I/R, P = 0.03; rhabdomyolysis, P = 0.045; Fig. 6 , C and D).
MIF reduces tubular cell death in vitro
In vitro, using both full or starvation medium, treatment of WT pmTECs with rMIF (100 ng/ml) during hypoxia for 24 hours (<1% O 2 ) significantly reduced cytotoxicity as shown morphologically ( Fig. 7A) and by the release of lactate dehydrogenase (LDH) (full medium, P = 0.003; starving medium, P ≤ 0.001; Fig. 7B ). Similarly, pmTECs challenged with hypoxia for 18 hours followed by 6 hours of normoxia (~20% O 2 ) and treated with rMIF displayed significantly reduced LDH release when compared to PBS treatment (full medium, P = 0.001; starving medium, P = 0.02; fig. S5 ). In addition, incubation with rMIF (100 and 500 ng/ml) reduced the phosphorylation of MLKL after hypoxia ( fig. S6B) . In vitro treatment of Mif −/− pmTECs with rMIF in hypoxia did not show significant cytoprotective effects (P = 0.09; Fig. 7C ).
rMIF administration in vivo reduces AKI
In WT mice, treatment with rMIF 30 min before and 6 hours after I/R injury significantly mitigated AKI after 24 hours of reperfusion. Compared to vehicle-treated mice, rMIF treatment significantly reduced serum creatinine (P = 0.03; Fig. 7E ) and the extent of tu bular injury, apoptosis, and necroptosis (Fig. 7, F and analyzed cell death and oxidative stress. In vitro, cytotoxicity was ameliorated by pretreatment with rMIF plus sCD74 (P = 0.002) or with sCD74 alone (P = 0.03; Fig. 8A ). Intracellular GSH in the setting of oxidative stress was more potently restored by coincubation with rMIF and sCD74 compared to rMIF alone (Fig. 8B ). In the setting of I/R injury in vivo, sCD74 administration 30 min before and 6 hours after ischemia did not significantly reduce serum cre atinine (Fig. 8,  C and D) . How ever, mice treated with sCD74 had significantly reduced tubular injury (P = 0.03) and a significantly reduced number of pMLKL-positive tubules in the renal cortex (P = 0.045; Fig. 8E ). mice was analyzed after 35 min of ische mia and 6 hours of reperfusion (n = 10 both groups), 35 min of is chemia and 24 hours of reperfusion (n = 5 both groups), and 24 hours after the induction of rhabdomyolysis (n = 10 both groups). (D) Relative mRNA expression of Cxc1 in kidney tissue of Mif-deficient and WT mice after 6 hours of I/R injury. Cxcl1, chemokine (C-X-C motif) ligand 1; ErHr3, Er-Hematopoiesis related-3; F4/80, monocytes/macrophages marker; Ly6G, lymphocyte antigen 6 complex locus G6D. Scale bars, 100 m. Data are means ± SD; *P < 0.05, **P < 0.01 analyzed by Student's t test.
DISCUSSION
Postoperative AKI in patients after cardiac surgery is associated with a complicated postoperative course and an excess in mortality (4). Despite substantial improvements in surgical techniques, perfusion, and anesthesiological management, the incidence and morbidity of AKI of patients undergoing cardiac surgery remain high (4). This necessitates a better understanding of the pathophysiology of AKI, which could lead to better risk stratification or new therapeutic approaches. Our findings provide preliminary evidence for a potentially beneficial role of increased circulating MIF in the prevention of AKI in patients undergoing cardiac surgery. Serum MIF increased rapidly in the perioperative setting, and in a small cohort of patients with kidney tumor enucleation, we identified renal ischemia as another stimulus for MIF release. In cardiac surgery patients, serum MIF was inversely correlated with the tubular injury marker NGAL. The increase in postoperative MIF was not only associated with reduced risk of AKI in general but was also associated with a markedly decreased occurrence of more severe grades of AKI (AKIN II and AKIN III).
These clinical studies do not establish a causative relationship between elevated serum MIF and postoperative AKI on a mechanistic level. Therefore, we extended the clinical findings by performing experimental studies in mouse models to clarify the role of MIF in noninfectious AKI. Using a model of renal I/R injury by cross-clamping of the renal artery, we mimicked the clinical setting of hemodynamic instability, inflammatory response, and release of ROS seen in cardiac surgery patients with postoperative development of AKI. In extension, we included a model of rhabdomyolysis, a commonly observed perioperative condition that con tributes to the risk of postoperative AKI in cardiac surgery patients (7) (8) (9) . In these models, Mif deficiency significantly aggravated the extent of kidney injury, indicating a fundamental role of MIF in kidney protection. Augmentation of serum MIF by perioperative rMIF injection in WT mice mitigated the severity of ische mic AKI. This result suggests that circulating MIF from sources other than the kidney, such as injured endothelium in the heart, might also be involved in protection against renal injury. It further supports the hypothesis that MIF might act as a beneficial, systemic stress-regulating mediator within the inflammatory response and thus may open future therapeutic approaches to reduce the risk of postoperative AKI by perioperative application of rMIF or smallmolecular weight MIF agonists (15) .
In the heart, the protective role of MIF in I/R injury has been attributed to signaling through the CD74/CD44/AMPK pathway, which was shown to increase glucose uptake into the cells (14) . However, previous studies in kidneys have demonstrated that there is no difference in the severity of AKI between WT and Ampkdeficient mice, suggesting that the MIFdependent CD74/AMPK signaling pathway might not be critically involved in AKI (33) .
AKI is characterized by tubular epithelial injury and cell death, the latter appearing morphologically as necrosis and therefore termed "tubular necrosis" (34) . Although morphologically indistinguishable from necrosis, recently, alternative regulated cell death pathways, such as necroptosis and ferroptosis, were shown to be crucially involved in tubular injury in AKI, potentially being more important than apoptosis (25, 27, 28) . Previous studies have reported that MIF may mediate antiapoptotic effects under specific conditions, such as hypoxic neuronal loss and cancer (35) (36) (37) (38) . In line with this, we found aggravated ap optosis in Mif −/− mice after I/R injury and rhabdomyolysis-although this remained an uncommon event. Mif-deficient mice also displayed significantly more pMLKL-positive, necroptotic tubules and a higher amount of lipid peroxidation, an indicator of ferroptosis. In this context, the increased non phosphorylated MLKL expression detected by immunohistochemistry may indicate an additional independent fac tor that lowers the threshold for necroptosis. Our study dem onstrates that MIF may have an important role in limiting necroptosis and ferroptosis in AKI.
Ferroptosis was demonstrated to occur in a synchronized manner in renal tubules, resulting in the breakdown of entire functional units (26) , but the initial trigger that ignites this cascade remains controversial. Our data on whole, pMLKL-positive, necroptotic tubule segments are in line with this concept of synchronized tubular necroptosis or ferroptosis, in which MIF might be involved as a counterregulatory factor. In the setting of Mif deficiency, this is potentially explained by sensitization to ferroptosis and necroptosis by an imbalance in redox sys tems. In vivo, this imbalance was mirrored by reduced GSH in Mif −/− kidney tissues. Besides, cardiac surgery patients with high serum MIF directly after surgery displayed a higher total antioxidant capacity compared to patients with low serum MIF. Thus, the protective effect of MIF might include the reduction of oxidative stress by its intrinsic TPOR activity (23, (39) (40) (41) (42) . The proposed action of MIF in the setting of cardiac surgery-related AKI is illustrated in In vitro biological n = 3; 6 hours I/R n = 10; 24 hours I/R n = 5, rhabdomyolysis n = 10. Data are means ± SD; *P < 0.05, **P < 0.01 analyzed by Student's t test. fig. S7 . The potentially protective action of MIF on these newly identified cell death pathways might also play a role in other organs where MIF has been shown to exhibit protection via the reduction of regulated necrosis and apoptosis, in tissues such as the heart and lung (15, 43) . The soluble form of the MIF receptor CD74, sCD74, is implicated in multiple inflammatory diseases (17, 30, 44) and was shown to form circulating complexes with MIF. In vitro, low amounts of sCD74 inhibited MIF signaling, whereas high amounts of sCD74 further promoted MIF's signal ing activity (17, 44) . In a cohort of cardiac surgery patients, preliminary data indicated a reduced incidence of AKI in patients with detectable sCD74-MIF complexes compared to patients without de tectable sCD74-MIF complexes in their blood (30) . It was shown that sCD74-MIF com plex formation increases MIF catalytic TPOR activity, indicating a potentially protective mechanism that increases MIF's antioxidant activity (30) . We found that pretreatment of tubular epithelial cells with sCD74 and MIF before stimulation with H 2 O 2 (mimicking reperfusion injury) reduced oxidative stress compared to PBS or MIF treatment alone. In the setting of I/R injury in mice, the additional administration of sCD74 resulted in a nonsignificant trend toward reduced tubular cell injury and alleviated AKI. However, we are aware that these preliminary findings should be considered cautiously and require further in-depth analysis of the exact underling molecular mech anisms. Studies of dosing and timing of sCD74 injection will be required to confirm the pro tective role of sCD74 in AKI.
In autoimmune kidney dis eases that affect glomeruli (crescentic glomerulonephritis or lupus nephritis), MIF was shown to aggravate inflammation via its chemokine-like functions (45) . During ische mic AKI, we found that immune cell infiltration was enhanced in Mif − /− mice com pared to WT mice. This finding is in line with the increased extent of cell death, which is a major driver of inflammation due to the release of highly im munogenic damage-associated molecular patterns and the production of proinflammatory cytokines (46) referred to as necroinflammation (28, 47) . These data also indicate that the protective effects of MIF against cell death might be more potent and supervene the potentially proinflammatory and chemokine-like effects of MIF in AKI.
There are limitations to our analyses that need to be considered. The results obtained from our observational, clinical study remain correlative and do not necessarily show a causative relationship. Follow-up large-scale clinical studies to validate the clinical significance of circulating MIF as an effective tool for perioperative risk stratification will be required. For therapeutic applications of MIF in humans, clinical validation of rMIF orthologs is necessary. A further limitation of our in vivo and in vitro experimental studies is that renal I/R injury or rhabdomyolysis are models that only partly mimic the pathophysiology of cardiac surgery-associated AKI. Although ischemia, oxidative stress, inflammation, and rhabdomyolysis are all recognized mechanisms, additional and complex individual clinical factors are implicated in AKI in cardiac surgery patients, which cannot be fully addressed with in vivo or in vitro models. In I/R injury, MIF treatment in WT mice protected against AKI and tubular injury, whereas MIF administration in Mif − /− mice did not show significant effects. A potential explanation of the divergent effects is the altered MIF co-receptor expression of CD44 in Mif − /− mice (48, 49) . Previous studies demonstrated that the CD44 receptor expression is MIF-dependent and that Mif − /− mice display a suppressed CD44 receptor expression in the kidney (48, 50) . Cd44 deficiency prevents MIF signaling via CD74 (49) . Therefore, a down-regulated CD44 receptor expression could be an explanation for the lack of effectiveness of the investigated MIF treatment in Mif − /− mice. Because WT mice are more comparable to the investigated patients (without Mif deficiency), we suggest that the obtained results of MIF treatment in WT mice better reflect the clinical setting.
The presented findings highlight a potential renoprotective role of MIF in AKI, which may be of particular clinical significance after cardiac surgery. Mechanistically, we found that MIF potently limits necroptosis and mitigates oxidative stress by restoring intracellular GSH and reducing lipid peroxidation, both of which are considered hallmarks of ferroptosis (51, 52) . The identified protective effects of MIF may open future perspectives for perioperative risk stratification and potential therapeutic options to reduce the incidence of AKI in cardiac surgery patients by application of MIF homologs to augment MIF's cytoprotective actions intraoperatively.
MATERIALS AND METHODS

Study design
This study was designed to investigate the role of MIF in AKI. The clinical study was designed as a prospective, observational study (ClinicalTrials.gov: NCT 02488876), and after screening for eligibility, 60 patients were successfully enrolled after receiving informed consent in the period from September 2015 to March 2016 ( fig. S1) mice on a C57/Bl6 background were used in this study. Mif −/− mice were generated as previously reported (45) . Two noninfectious models were used to mimic postoperative AKI: I/R injury induced by clamping the renal artery and glycerol injection into the muscle to induce rhabdomyolysis. A subset of mice that received I/R injury was subjected to contralateral nephrectomy. Mice (at least n = 5 per group) were treated with rMIF or sCD74 before or after I/R, and blood and tissue were analyzed. pmTECs were used at passage 3 for in vitro analysis under hypoxic and normoxic conditions. Additional details can be found in Supplementary Materials and Methods, including a list of antibodies used for immunohistochemical staining (table S2) .
Patients undergoing cardiac surgery
All patients were scheduled for elective, cardiac surgery with the use of aortic cross-clamping, cardioplegic myocardial arrest, and CPB.
The patients were consecutively enrolled after written informed consent was obtained. Exclusion criteria were emergency operations, pregnancy, lack of informed consent, and age less than 18 years. Serum samples were drawn 1 day before surgery, immediately postoperatively (0 hours), and 6, 12, and 24 hours after admission to the intensive care unit (ICU). After blood collection, the samples were centrifuged (3000 rpm for 10 min), and the supernatants were transferred to cryotubes for storage at −80°C until final analysis. Urine samples were collected preoperatively, immediately postoperatively, and 24 hours after admission to the ICU and were transferred to cryotubes for storage at −80°C. The development of AKI was classified in accordance with the AKIN criteria within 72 hours after cardiac surgery ( fig. S1B) (20) .
Patients undergoing kidney tumor enucleation
Because CPB is associated with a transient decrease in renal perfusion, we investigated whether renal ischemia itself induces MIF secretion into the bloodstream. Serum MIF of patients undergoing kidney tumor enucleation was analyzed as a predefined secondary analysis of a recently completed study (ethical committee vote 012/13, registered on ClinicalTrials.gov as NCT: NCT01839084). Of 46 patients, 18 patients were exposed to renal I/R by cross-clamping of the renal artery during the surgical procedure for 6 to 35 min. Patients who received an unexpected total nephrectomy intraoperatively were excluded from subsequent analysis. Anesthesia, perioperative medication, surgical procedure, and treatment in the ICU were performed in accordance with the local standards, as previously described (30) . Serum samples were drawn 1 day before surgery (pre-OP), 5 min after tumor enucleation (intra-OP), in the recovery room shortly after the termination of surgery, and on POD1. Subsequently, the samples were transferred to cryotubes for storage at −80°C until final analysis.
Statistical analysis
Experimental and clinical data were statistically analyzed using a commercially available software package, SPSS 19.0 (SPSS Inc.). GraphPad Prism (GraphPad Software Inc.) was used to generate figures. All metric data were tested for normal distribution using the Shapiro-Wilk W test. Given the explorative nature of this study, normally distributed results of single measurements were compared between the groups at different time points after surgery using Student's t test. Post hoc testing was performed using the Bonferroni test. Non-normally distributed single measurements were compared using the Mann-Whitney U test. Nonparametric data were compared using the Fisher's exact test. For correlation studies, linear regression analysis was performed using the Pearson correlation coefficient. In all cases, P < 0.05 was considered statistically significant, and two-sided testing was used.
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